???jsp.layout.hku.browse.grant_fundingyear???

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中 >>

Browse by Funding Year 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Showing results 1 to 19 of 19

	Project Title	Principal Investigator	Year
1	A 12-week, double-blind, randomized study to investigate the effect of 500mcg roflumilast tablets once daily versus placebo on pulmonary function in patients with chronic obstructive pulmonary disease	Ho, James Chung Man	2005/2006
2	International, randomized, open-label, phase 3, trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first line treatment of patients with advanced non-small cell lung cancer	Ho, James Chung Man	2006/2007
3	A Phase III, radonmized, double-blinded, parallel group, multi centre study to access the efficacy and safety of ZD6474 (ZACTIMA TM) in combination with pemetrexed (Alimta) versus pemetrexed alone in patients with locally-advanced or metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) after failure of 1st line anti-cancer therapy	Ho, James Chung Man	2006/2007
4	Open label, prospective, double arm, randomized, pilot study to evaluate the safety and efficacy of the same day administration of PDT with verteporfin and an intravitreal injection of ranibizumab vs. ranibizumab monotherapy for the treatment of subfoveal CNV secondary to neovascular age related macular degeneration in the Asian population	Lai, Wai Kwan Wico	2007/2008
5	A rabdomized, double blind, placebo controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer	Ho, James Chung Man	2007/2008
6	A Phase 3, multicentre, randomized, placebo-controlled, double-bind trial of AMG 706 in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer	Ho, James Chung Man	2007/2008
7	A phase III, randomized, double-blind, active-controlled, parallel-group study, conducted under in-house building conditions, to examine the safety, tolerability, and efficacy of a single dose of intravenous MK-0517 for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated wtih Cisplatin chemotheray	Ho, James Chung Man	2008/2009
8	A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7,5mg.kg or 15mg/kg) in addition to carboplain-based chemotherapy (gemcitabine or paclitaxed)	Ho, James Chung Man	2008/2009
9	A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC)	Ho, James Chung Man	2008/2009
10	Multicenter, randomized, double-blind, phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy	Ho, James Chung Man	2008/2009
11	A Phase III, multi-center, placebo-controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens.	Ho, James Chung Man	2009/2010
12	Phase 2, open-label single arm study of the efficacy and safety of PF 02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus	Ho, James Chung Man	2010/2011
13	Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus	Ho, James Chung Man	2010/2011
14	A multicenter randomised double blind placebo controlled study of AMG785 in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture status post definitive fracture fixation with an intramedullary nail	Leung, Frankie Ka Li	2010/2011
15	Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment	Ho, James Chung Man	2010/2011
16	A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarcevar) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene	Ho, James Chung Man	2010/2011
17	Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC)	Ho, James Chung Man	2010/2011
18	Study of immunopathogenesis of multiple sclerosis and neuromyelitis optica	Chan, Koon Ho	2011/2012
19	A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM	Ho, James Chung Man	2011/2012